Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402531 · ClinicalTrials.gov registry record · Phase 2
Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01402531 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 10 participants.
The verdict
NCT01402531, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).
Interventions
- DRUG Submucosal Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07-22 |
| Est. Completion | 2013-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01402531
The ClinicalTrials.gov registry entry for NCT01402531 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Submucosal Bevacizumab is the first listed.
NCT01402531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01402531 about?
NCT01402531 is a clinical study titled "Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)". This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).
What is the current status of trial NCT01402531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-07-22. Estimated completion is 2013-07-27.
What interventions are being tested in trial NCT01402531?
The interventions under investigation include: Submucosal Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01402531?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.